ArticleBritish journal of cancer2012
Calprotectin: a novel biomarker for the diagnosis of pleural effusion.
Article in British journal of cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Calprotectin as a Biomarker for Infectious Diseases: A Comparative Review with Conventional Inflammatory Markers.International journal of molecular sciences · 2025Review
- Interleukin -39 Expression in Pleural Effusion and Its Diagnostic Value for Tuberculous Pleurisy.Journal of inflammation research · 2025Article
- Evaluation of DiaSorin LiaisonAdvances in laboratory medicine · 2023Article
- Article
- Pleural biomarkers in diagnostics of malignant pleural effusion: a narrative review.Translational lung cancer research · 2021Review
- Calprotectin in Lung Diseases.International journal of molecular sciences · 2021Review
- Article
- Pleural Fluid suPAR Levels Predict the Need for Invasive Management in Parapneumonic Effusions.American journal of respiratory and critical care medicine · 2020Observational
- Combined serum biomarkers in the noninvasive diagnosis of complicated parapneumonic effusions and empyema.BMC pulmonary medicine · 2019Article
- Proteome profiling reveals novel biomarkers to identify complicated parapneumonic effusions.Scientific reports · 2017Article
- Highly Sensitive Marker Panel for Guidance in Lung Cancer Rapid Diagnostic Units.Scientific reports · 2017Article
- A Novel Combination of Calprotectin and CXCL12 for Predicting Malignancy in Patients with Exudative Pleural Effusion.Medicine · 2015Article
- Serum calprotectin, CD26 and EGF to establish a panel for the diagnosis of lung cancer.PloS one · 2015Article
- Evaluation of pleural effusion sCD26 and DPP-IV as diagnostic biomarkers in lung disease.Scientific reports · 2014Article
- Adenosine deaminase-based measurement in the differential diagnosis of pleural effusion: a multicenter retrospective study.Therapeutic advances in respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNovel non-invasive biomarkers for the precise diagnosis of malignancy in pleural effusion (PE) are needed. The aim of this study was to determine the diagnostic accuracy of calprotectin for predicting malignancy in patients with exudative PE.
methodsCalprotectin concentration was measured in 156 individuals diagnosed with exudative PE (67 malignant and 89 benign). Calprotectin accuracy for discriminating between malignant and benign PE was evaluated using receiver operating characteristic (ROC) curves. Univariate and multivariate logistic regression were performed to test the association between calprotectin levels and malignant PE.
resultsCalprotectin levels were significantly lower in malignant pleural fluid (257.2 ng ml(-1), range: 90.7-736.4) than benign effusions (2627.1 ng ml(-1), range: 21-9530.1). The area under the curve was 0.963. A cutoff point of ≤ 736.4 ng ml(-1) rendered a sensitivity of 100%, with a specificity of 83.15%, which could prove useful to delimit those patients with negative cytology tests that should be referred for more invasive diagnostic procedures. Logistic regression demonstrated a strong association between calprotectin and malignancy (adjusted OR 663.14).
conclusionCalprotectin predicts malignancy in pleural fluid with high accuracy and could be a good complement to cytological methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.